NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Xingruida XDR

Published 12 Nov 2026. 38-page investigative report on who is behind Xingruida XDR: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Xingruida XDR is not a blanket vendor call; it is a compound-by-compound call. Across 94 Finnrick lab tests, the overall record is 66 pass / 28 fail, for a 70% pass rate. The strongest usable signal sits in Tirzepatide and Retatrutide, which have the deepest and most defensible records in this catalog, while Tesamorelin, BPC-157 and TB-500 are the side of the file where buyers should not borrow confidence from the incretin results. GHK-Cu is also cautionary because its record is fail-heavy despite a middling headline rating.

The non-lab record adds a second layer of buyer risk. UK Companies House shows a same-name Xingruida company dissolved in September 2026 after only incorporation and Gazette filings; the Hong Kong trade-company layer remains live but does not publicly resolve directors, shareholders or the storefront’s ultimate controller. The site presents manufacturer, R&D and QC language, but the public record reviewed did not identify a named plant, licence, GMP certificate, responsible chemist, batch-release authority or public lot-verification workflow.

The storefront also sits in a messy channel environment. A mainstream purchase account names a sales rep called Jasmine, bitcoin payment and a shipment description unrelated to the contents, but it is only a single-vial story. Separately, the report maps shared infrastructure and exact testimonial reuse with Mammoth Biotech, plus a November 2026 brand-keyword doorway network that redirects search traffic to rotating U.S. WhatsApp numbers using a fixed first-order discount pitch. The report does not attribute that doorway network to Xingruida; it treats it as an authentication hazard for buyers trying to reach the real vendor.

Inside the full report:

  • Per-product pass/fail rates, rating trajectories and methodology-divergence charts for all 9 tested products
  • Companies House, Hong Kong registry and directory evidence for the UK and Hong Kong entity trail
  • Storefront-claim review covering manufacturing proof, factory images, policy shells, payment rails and COA verification gaps
  • Infrastructure analysis of hkxingruida.com, including DNS, IIS/ASP hosting, certificate history and the Mammoth Biotech overlap
  • Brand-keyword hijack analysis covering peptides16.com, fzpefa.com, injected academic pages and the WhatsApp redirect pool

Risk assessment

  • Tesamorelin, BPC-157 and TB-500 quality risk — high: Tesamorelin is 54.74% across 10 tests (6 pass / 4 fail), BPC-157 is 53.66% across 8 tests (5 pass / 3 fail), and TB-500 is 42.78% across 3 tests (2 pass / 1 fail).
  • Corporate continuity and recourse risk — high: UK company No. 16344395 was dissolved on 22 Sep 2026 after filing no accounts or confirmation statement; the storefront names no contracting party.
  • Unverified manufacturing-claim risk — high: The site claims manufacturer, R&D and QC capability but discloses no named plant, manufacturing legal entity, licence, GMP certificate, responsible chemist or public lot-verification workflow.
  • Brand-impersonation and rogue WhatsApp funnel risk — high: A November 2026 doorway network used the Xingruida keyword to route buyers to 14 US WhatsApp numbers; the vendor warns of impostors but provides no authorised-channel list or anti-counterfeit workflow.
  • Lot-validation risk in Tirzepatide and Retatrutide — medium: Tirzepatide 78.86% (24 tests, 19/5) and Retatrutide 77.58% (32 tests, 25/7) lead the catalog, but each has multiple failures and should be bought only with current-lot proof.
  • Low-depth or fail-heavy product risk in GHK-Cu, PT-141, Melanotan II and Ipamorelin — medium: GHK-Cu is 4 pass / 5 fail (70.44%); PT-141 is 1 pass / 2 fail (60.25%); Melanotan II is 1 pass / 1 fail (60.97%); Ipamorelin is 3 pass / 0 fail (73.1%) but only 3 tests.
  • Related-storefront and sourcing opacity risk — medium: Mammoth Biotech shares IP, IIS/ASP stack, peptide category and exact testimonial text with Xingruida; ownership, inventory and payment links are undisclosed.
  • Misleading operating-history risk — medium: The news page presents 2016-dated posts on a domain registered 27 Mar 2025, and homepage scale counters display zero; public longevity cannot be established from the site presentation.